Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

Molecular Oncology

Volumn 7, Issue 6, 2013, Pages 1103-1115

  Borgo, Christian ^a   Cesaro, Luca ^a   Salizzato, Valentina ^a   Ruzzene, Maria ^a   Massimino, Maria Lina ^a   Pinna, Lorenzo A ^a   Donella Deana, Arianna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bcr Abl; Chronic myeloid leukaemia; CK2; Imatinib resistance; Inhibitor

Indexed keywords

BCR ABL PROTEIN; CASEIN KINASE II; CX 4945; IMATINIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CATALYSIS; CELL FRACTIONATION; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FLUORESCENCE; GENE AMPLIFICATION; IMMUNOLOCALIZATION; IMMUNOPRECIPITATION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SEDIMENTATION; SIGNAL TRANSDUCTION; UPREGULATION;

BCR-ABL; CHRONIC MYELOID LEUKAEMIA; CK2; IMATINIB-RESISTANCE; INHIBITOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASEIN KINASE II; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NAPHTHYRIDINES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84887869270     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.08.006     Document Type: Article

References (42)

1. Adrián F.J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding S., Manley P., Mestan J., Fabbro D., Gray N.S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2006, 2:95-102.
2. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2-a key suppressor of apoptosis. Adv. Enzym. Regul. 2008, 48:179-187.
3. Barnes D.J., Palaiologou D., Panousopoulou E., Schultheis B., Yong A.S.M., Wong A., Pattacini L., Goldman J.M., Melo J.V. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005, 65:8912-8919.
4. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol. Am. Soc. Hematol. Educ. Prog. 2009, 461-476.
5. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
6. Cilloni D., Saglio G. Molecular pathways: BCR-ABL. Clin. Cancer Res. 2012, 18:930-937.
7. de Jong R., ten Hoeve J., Heisterkamp N., Groffen J. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 1997, 14:507-513.
8. Di Maira G., Salvi M., Arrigoni G., Marin O., Sarno S., Brustolon F., Pinna L.A., Ruzzene M. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 2005, 12:668-677.
9. Di Maira G., Brustolon F., Bertacchini J., Tosoni K., Marmiroli S., Pinna L.A., Ruzzene M. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007, 26:6915-6926.
10. Di Maira G., Brustolon F., Tosoni K., Belli S., Krämer S.D., Pinna L.A., Ruzzene M. Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol. Cell. Biochem. 2008, 316:155-161.
11. Filhol O., Cochet C. Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell. Mol. Life Sci. 2009, 66:1830-1839.
12. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N.Engl. J. Med. 2003, 349:1451-1464.
13. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
14. Hériché J.K., Chambaz E.M. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 1998, 17:13-18.
15. Kang H.S., Welch W.J. Characterization and purification of the 94-kDa glucose-regulated protein. J.Biol. Chem. 1991, 266:5643-5649.
16. Keeshan K., Mills K.I., Cotter T.G., McKenna S.L. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001, 15:1823-1833.
17. le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L., Cabrita G., Marchesi E., Supino R., Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
18. Lolli G., Pinna L.A., Battistutta R. Structural determinants of protein kinase CK2 regulation by autoinhibitory polymerization. ACS Chem. Biol. 2012, 7:1158-1163.
19. Matsumoto Y., Takano H., Kunishio K., Nagao S., Fojo T. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells. Jpn. J. Cancer Res. 2001, 92:778-784.
20. Meggio F., Donella-Deana A., Ruzzene M., Brunati A.M., Cesaro L., Guerra B., Meyer T., Mett H., Fabbro D., Furet P., Dobrowolska G., Pinna L.A. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 1995, 234:317-322.
21. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17:349-368.
22. Mishra S., Reichert A., Cunnick J., Senadheera D., Hemmeryckx B., Heisterkamp N., Groffen J. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003, 22:8255-8262.
23. Mishra S., Pertz V., Zhang B., Kaur P., Shimada H., Groffen J., Kazimierczuk Z., Pinna L.A., Heisterkamp N. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007, 21:178-180.
24. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J.Clin. Invest. 2010, 120:2254-2264.
25. Phan-Dinh-Tuy F., Henry J., Boucheix C., Perrot J.Y., Rosenfeld C., Kahn A. Protein kinases in human leukemic cells. Am. J. Hematol. 1985, 19:209-218.
26. Piazza F., Manni S., Ruzzene M., Pinna L.A., Gurrieri C., Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012, 26:1174-1179.
27. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., Gewirtz A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 2004, 10:1187-1189.
28. Quintás-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
29. Redaelli S., Boschelli F., Perini P., Pirola A., Viltadi M., Gambacorti-Passerini C. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia 2010, 24:1223-1227.
30. Roychowdhury S., Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev. 2011, 25:279-290.
31. Ruzzene M., Di Maira G., Tosoni K., Pinna L.A. Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol. 2010, 484:495-514.
32. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim. Biophys. Acta 2010, 1804:499-504.
33. Salvi M., Sarno S., Cesaro L., Nakamura H., Pinna L.A. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim. Biophys. Acta 2009, 1793:847-859.
34. Santos F.P.S., Kantarjian H., Quintás-Cardama A., Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011, 17:465-476.
35. Sarno S., Vaglio P., Meggio F., Issinger O.G., Pinna L.A. Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J.Biol. Chem. 1996, 271:10595-10601.
36. Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O'Brien S.E., Bliesath J., Omori M., Huser N., Ho C., Proffitt C., Schwaebe M.K., Ryckman D.M., Rice W.G., Anderes K. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits pro-survival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010, 70:10288-10298.
37. St-Denis N.A., Litchfield D.W. Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell. Mol. Life Sci. 2009, 66:1817-1829.
38. Stegmeier F., Warmuth M., Sellers W.R., Dorsch M. Targeted cancer therapies in the twenty-first century:lessons from imatinib. Clin. Pharmacol. Ther. 2010, 87:543-552.
39. Trembley J.H., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. Life Sci. 2009, 66:1858-1867.
40. Vilk G., Weber J.E., Turowec J.P., Duncan J.S., Wu C., Derksen D.R., Zien P., Sarno S., Donella-Deana A., Lajoie G., Pinna L.A., Li S.S., Litchfield D.W. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells. Cell Signal 2008, 20:1942-1951.
41. Virgili A., Nacheva E.P. Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines. Mol. Cytogenet. 2010, 3:15.
42. Zanin S., Borgo C., Girardi C., O'Brien S.E., Miyata Y., Pinna L.A., Donella-Deana A., Ruzzene M. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells. PLoS One 2012, 7:e49193.